

SEQUENCE LISTING

<110> VALTANEN, Heli et. al.

<120> METHOD FOR DESIGNING PEPTIDES

<130> 0933-0238PUS1

<140> US 10/528,989

<141> 2005-03-24

<150> PCT/FI2003/000705

<151> 2003-09-29

<160> 27

<170> PatentIn version 3.3

<210> 1

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic intein Fwd ~~S~~apI primer

<400> 1

cctttctgct cttccaaacgc cgacggggct

30

<210> 2

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic intein Rev PstI primer

<400> 2

actttcaacc tgcagttacc cagcggccccc

30

<210> 3

<211> 59

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic oligonucleotide encoding SEQ ID NO: 10

<400> 3

ggtgttgctc ttccaaactgt acgaccatt ggggatttac tttatgttaa ctgcaggcg 59

<210> 4

<211> 15

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic primer used to convert SEQ ID NO: 3 to double-stranded form

<400> 4

cgcctgcagt taaca

15

<210> 5

<211> 75

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic degenerate oligonucleotide used in the cloning of the intein-peptide fusions

<400> 5

ggtggttgct cttccaaacgg ccggccvavva vtatvavggc tgtaccaccc atttacttta 60
tgttaactgc aggcg 75

<210> 6

<211> 17

<212> DNA

<213> Artificial Sequence

<220>

<223> Transposon specific primer

<400> 6

atcagcggcc gcgatcc

17

<210> 7

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Transposon specific primer

<400> 7

ttattcggtc gaaaaggatc c

21

<210> 8

<211> 4

<212> PRT

<213> Unknown

<220>

<223> Peptide derived from phage

<400> 8

Ala Asp Gly Ala

1

<210> 9
<211> 4
<212> PRT
<213> Unknown

<220>
<223> Peptide derived from phage

<400> 9
Gly Ala Ala Gly
1

<210> 10
<211> 10
<212> PRT
<213> Unknown

<220>
<223> Recombinant peptide prepared by the intein system

<400> 10
Cys Thr Thr His Trp Gly Phe Thr Leu Cys
1 5 10

<210> 11
<211> 10
<212> PRT
<213> Unknown

<220>
<223> Non-cyclic synthetic control peptide

<400> 11
Ser Thr Thr His Trp Gly Phe Thr Leu Ser
1 5 10

<210> 12
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Ala-substitution of the CTT-peptide

<400> 12
Cys Ala Thr His Trp Gly Phe Thr Leu Cys
1 5 10

<210> 13
<211> 10

<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Ala-substitution of the CTT-peptide

<400> 13
Cys Thr Ala His Trp Gly Phe Thr Leu Cys
1 5 10

<210> 14
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Ala-substitution of the CTT-peptide

<400> 14
Cys Thr Thr Ala Trp Gly Phe Thr Leu Cys
1 5 10

<210> 15
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Ala-substitution of the CTT-peptide

<400> 15
Cys Thr Thr His Ala Gly Phe Thr Leu Cys
1 5 10

<210> 16
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Ala-substitution of the CTT-peptide

<400> 16
Cys Thr Thr His Trp Ala Phe Thr Leu Cys
1 5 10

<210> 17
<211> 10
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Ala-substitution of the CTT-peptide

<400> 17

Cys Thr Thr His Trp Gly Ala Thr Leu Cys
1 5 10

<210> 18

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Ala-substitution of the CTT-peptide

<400> 18

Cys Thr Thr His Trp Gly Phe Ala Leu
1 5

<210> 19

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Ala-substitution of the CTT-peptide

<400> 19

Cys Thr Thr His Trp Gly Phe Ala Leu Cys
1 5 10

<210> 20

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:

CTT-peptide with a tryptophan analogue at position 5

<220>

<221> misc_feature

<222> (5)..(5)

<223> Xaa at position 5 is 5-OH-Trp, 5-F-Trp or 6-F-Trp

<400> 20

Cys Thr Thr His Xaa Gly Phe Thr Leu Cys
1 5 10

<210> 21

<211> 10

<212> PRT

<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Control sequence

<400> 21
Cys Glu Arg Gly Gly Leu Glu Thr Ser Cys
1 5 10

<210> 22
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Control sequence
<400> 22
Cys Pro Cys Phe Leu Leu Gly Cys Cys
1 5

<210> 23
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
CTT-peptide with additional hydrophilic amino acids

<220>
<221> misc_feature
<222> (3)..(4)
<223> Xaa at positions 3 and 4 is any hydrophilic amino acid

<220>
<221> misc_feature
<222> (6)..(6)
<223> Xaa at position 6 is any hydrophilic amino acid

<400> 23
Gly Arg Xaa Xaa Tyr Xaa Gly Cys Thr Thr His Trp Gly Phe Thr Leu
1 5 10 15

Cys

<210> 24
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
CTT-peptide with additional hydrophilic amino acids

<400> 24

Gly Arg Glu Asn Tyr His Gly Cys Thr Thr His Trp Gly Phe Thr Leu
1 5 10 15

Cys

<210> 25

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide derived from phage

<220>

<221> misc_feature

<222> (5)..(5)

<223> Xaa can be any naturally occurring amino acid and (X)n may be present or absent. Xaa at position 5 is the peptide insertion point.

<400> 25

Ala Asp Gly Ala Xaa Gly Ala Ala Gly
1 5

<210> 26

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: MMP-2 specific fluorescent peptide substrate

<220>

<221> MISC_FEATURE

<222> (1)..(1)

<223> Xaa is MCA

<220>

<221> MISC_FEATURE

<222> (5)..(5)

<223> Xaa is Nva

<220>

<221> MISC_FEATURE

<222> (6)..(6)

<223> Xaa is Dpa

<400> 26

Xaa Pro Leu Ala Xaa Xaa Ala Arg
1 5

<210> 27

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: recombinant peptide prepared by the
intein system

<400> 27

Cys Thr Thr His Trp Gly Phe Thr Ala Cys

1 5 10